Bicalutamide 50mg""'""'

Bicalutamide

BICALUMUTIDE 50   is a medication used in the treatment of prostate cancer, specifically in cases of advanced prostate cancer. It is classified as an antiandrogen, and it works by blocking the action of male sex hormones (androgens), particularly testosterone, which can fuel the growth of prostate cancer cells.

BICALUMUTIDE 50  is available under various brand names, including Casodex.

BICALUMUTIDE 50  is an androgen receptor antagonist. It competes with androgens like testosterone for binding to androgen receptors on prostate cancer cells. By blocking the androgen receptors, BICALUMUTIDE 50  prevents the androgens from signaling the cells to grow and divide.

1. BICALUMUTIDE 50  is primarily prescribed to treat prostate cancer, especially in cases where the cancer has spread locally or to other parts of the body. It is often used in combination with other treatments, such as surgical castration or gonadotropin-releasing hormone (GnRH) agonists, to maximize androgen blockade.

2. The dosage of  BICALUMUTIDE 50  can vary depending on the specific treatment plan and the individual's condition. It is typically taken orally in tablet form.

3. Common side effects may include hot flashes, breast tenderness or enlargement (gynecomastia), fatigue, and gastrointestinal symptoms. Rarely, it can cause liver toxicity, so regular monitoring of liver function is important during treatment.

4. It's important to inform your healthcare provider about any other medications you are taking, as drug interactions can occur.

   BICALUMUTIDE 50  should not be used during pregnancy, as it can harm the developing fetus. Women who are pregnant or may become pregnant should avoid handling the medication.
5. The duration of BICALUMUTIDE 50  treatment can vary depending on the progression of prostate cancer and the individual's response to therapy. It may be used as part of long-term maintenance therapy.

6. Regular monitoring of prostate-specific antigen (PSA) levels and other relevant tests is crucial to assess the effectiveness of treatment and monitor for potential side effects or complications.

7.  In some cases,  BICALUMUTIDE 50  may be used as adjuvant therapy (in addition to other treatments) after radiation therapy or surgery to reduce the risk of cancer recurrence in localized prostate cancer.

8. For further information please contact:

   info@sterispharma.com

   Order Now - https://www.sterisonline.com/product/bicalumutide-50-133654